<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230708058713N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-09-05</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of bone grafting method and the material on bone formation</public_title>
      <acronym></acronym>
      <scientific_title>comparison of the amount of bone structure by the GBR double-layer technique at the same time as placing the implant in the cosmetic area using FDBA and DFDBA</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-04-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72103</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>3 to 4 mm narrow ridge with a 4-wall defect in the buccal two-thirds of the cosmetic area.</hc_freetext>
      <i_freetext>Intervention 1: This study has two intervention groups as follows: the samples will be randomly divided into two groups of 40. In the first group, the implant intervention is performed at the same time as the two-layer technique GBR; Antibiotic prophylaxis is given before the procedure; Lidocaine infiltration anesthesia is used and the full thickness mucoperiosteal flap is performed without damaging the periosteum. The incision is made at the apex of the ridge while maintaining a sufficient amount of gingival attachment. Next, in the first group for GBR, 0.3 cc allograft FDBA with 500-1000 nm particles of CenoBone brand is placed in the first layer on the implant, and in the second layer, Ceno Membrane absorbable collagen membrane with a thickness of 0.6 1 mm; In the third layer, 0.3 cc DFDBA allograft with 500-1000 nm particles from Ceno Bone brand is placed, and finally intact periosteum is placed as the fourth layer. Intervention 2: Intervention group:In the second group, all steps are the same as the first group, with the difference that in the first layer, Ceno Bone brand DFDBA with particle size of 500 to 1000 nm is placed in the amount of 0.3 cc, and in the third layer, Ceno Bone brand FDBA with The size of the particles of 500 to 1000 nm is placed in the amount of 0.3 cc. Immediately after the treatment, CBCT is taken, and then the patient is called to close the Helling abutment six months after the treatment, and the amount of bone formation is measured in two groups.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only information about the main outcome

When:
The access period starts 6 months after the results are published

To whom:
Relevant academic and scientific institutions

Conditions:
It can be used to improve clinical skills and increase productivity of oral surgeries

Where to obtain:
Azad Islamic School of Dentistry, address: Pasdaran, 9th Nistan street, contact number: 22564571 and postal code: 19585.175

How to obtain:
The request will be made to Azad Islamic Medical Sciences Faculty and reviewed by the Research Council as soon as possible.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Raofe Asghari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ajodanie Avu. , 14th Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1956817451</zip>
        <telephone>+98 21 2280 2041</telephone>
        <email>Asghari.raha@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Ashagh Lasemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pasdaran avu. , 9th neyestan street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۹۵۸۵-۱۷۵</zip>
        <telephone>+98 21 2256 4571</telephone>
        <email>asghari.raha@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All patients have ASA = 1
They have extracted their teeth in front of the maxilla and referred after soft tissue healing.
Patients have a narrow ridge of 3 to 4 mm in the aesthetic zone.
The primary stability of used implants is above 35.
The age of the patients is 30 to 60 years.</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient does not have ideal systemic conditions (ASA should not be 1)
The patient is over 60 years old.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>This study has two intervention groups as follows: the samples will be randomly divided into two groups of 40. In the first group, the implant intervention is performed at the same time as the two-layer technique GBR; Antibiotic prophylaxis is given before the procedure; Lidocaine infiltration anesthesia is used and the full thickness mucoperiosteal flap is performed without damaging the periosteum. The incision is made at the apex of the ridge while maintaining a sufficient amount of gingival attachment. Next, in the first group for GBR, 0.3 cc allograft FDBA with 500-1000 nm particles of CenoBone brand is placed in the first layer on the implant, and in the second layer, Ceno Membrane absorbable collagen membrane with a thickness of 0.6 1 mm; In the third layer, 0.3 cc DFDBA allograft with 500-1000 nm particles from Ceno Bone brand is placed, and finally intact periosteum is placed as the fourth layer.</i_keyword>
      <i_keyword>Intervention group:In the second group, all steps are the same as the first group, with the difference that in the first layer, Ceno Bone brand DFDBA with particle size of 500 to 1000 nm is placed in the amount of 0.3 cc, and in the third layer, Ceno Bone brand FDBA with The size of the particles of 500 to 1000 nm is placed in the amount of 0.3 cc. Immediately after the treatment, CBCT is taken, and then the patient is called to close the Helling abutment six months after the treatment, and the amount of bone formation is measured in two groups.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Percentage of bone formation; Consistency of results. Timepoint: 6 months follow up. Method of measurement: The area filled in the cavity created in the bone using the comparison of two CBCTs at the beginning of the operation and 6 months follow-up.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-06-12</approval_date>
        <contact_name>Research Ethics Committees of Islamic Azad University- Dental Branch Tehran - Iran</contact_name>
        <contact_address>Ghods town, simaye iran street ,The central headquarters of the Ministry of Health and Medical Education Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
